Denali Therapeutics Inc.
Symbol: DNLI
NASDAQ
20.86
USDDzisiejsza cena rynkowa
-14.6980
Wskaźnik P/E
-0.2609
Wskaźnik PEG
2.88B
Kapitalizacja MRK
- 0.00%
Rentowność DIV
Denali Therapeutics Inc. (DNLI) Sprawozdania finansowe
Bilans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 4623.21 | 1034.5 | 1336.2 | 865.4 | |||||||||
balance-sheet.row.short-term-investments | 4147.99 | 907.4 | 1118.2 | 571.9 | |||||||||
balance-sheet.row.net-receivables | 9.3 | 2.7 | 5 | 1.2 | |||||||||
balance-sheet.row.inventory | -6.6 | 0 | -5 | 0 | |||||||||
balance-sheet.row.other-current-assets | 130.34 | 26.9 | 36.1 | 30.6 | |||||||||
balance-sheet.row.total-current-assets | 4756.24 | 1064.1 | 1372.3 | 897.2 | |||||||||
balance-sheet.row.property-plant-equipment-net | 283.89 | 71.6 | 74.5 | 69.6 | |||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.long-term-investments | 12.61 | 1.6 | 1.5 | 425.4 | |||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.other-non-current-assets | 53.03 | 16.5 | 11.9 | 11.9 | |||||||||
balance-sheet.row.total-non-current-assets | 349.53 | 89.8 | 87.9 | 506.9 | |||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-assets | 5105.77 | 1153.9 | 1460.2 | 1404.2 | |||||||||
balance-sheet.row.account-payables | 21.4 | 9.5 | 2.8 | 4.8 | |||||||||
balance-sheet.row.short-term-debt | 27.59 | 7.3 | 7.3 | 5.5 | |||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.long-term-debt-total | 191.16 | 45 | 53 | 58.6 | |||||||||
Deferred Revenue Non Current | 1.05 | 0 | 0.5 | 4.7 | |||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||
balance-sheet.row.other-current-liab | 270.01 | 61.2 | 63.8 | 47.7 | |||||||||
balance-sheet.row.total-non-current-liabilities | 193.36 | 45 | 53.9 | 63.6 | |||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.capital-lease-obligations | 211.49 | 45 | 60.4 | 58.6 | |||||||||
balance-sheet.row.total-liab | 802.96 | 123 | 417.8 | 441.9 | |||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.common-stock | 6.81 | 1.7 | 1.7 | 1.5 | |||||||||
balance-sheet.row.retained-earnings | -4091.1 | -1116.2 | -971 | -645 | |||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -3.97 | 0.6 | -6.9 | -2.5 | |||||||||
balance-sheet.row.other-total-stockholders-equity | 8391.07 | 2144.8 | 2018.6 | 1608.2 | |||||||||
balance-sheet.row.total-stockholders-equity | 4302.82 | 1031 | 1042.4 | 962.3 | |||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 5105.77 | 1153.9 | 1460.2 | 1404.2 | |||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-equity | 4302.82 | 1031 | 1042.4 | 962.3 | |||||||||
balance-sheet.row.total-liabilities-and-total-equity | 5105.77 | - | - | - | |||||||||
Total Investments | 4157.49 | 909 | 1118.2 | 997.4 | |||||||||
balance-sheet.row.total-debt | 218.75 | 52.2 | 60.4 | 58.6 | |||||||||
balance-sheet.row.net-debt | -256.47 | -74.9 | -157.7 | -234.9 |
Rachunek przepływów pieniężnych
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -145.22 | -145.2 | -326 | -290.6 | |||||||||
cash-flows.row.depreciation-and-amortization | 16.73 | 16.7 | 10.4 | 8.6 | |||||||||
cash-flows.row.deferred-income-tax | -56.28 | -2.4 | 0 | 8.7 | |||||||||
cash-flows.row.stock-based-compensation | 108.1 | 108.1 | 99.8 | 85.2 | |||||||||
cash-flows.row.change-in-working-capital | -289.93 | -289.9 | -24 | -20.4 | |||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.account-payables | 2.43 | 2.4 | 2.3 | 3.7 | |||||||||
cash-flows.row.other-working-capital | -292.36 | -292.4 | -26.3 | -24.1 | |||||||||
cash-flows.row.other-non-cash-items | 8.61 | -45.2 | -4.9 | -3 | |||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -357.99 | 0 | 0 | 0 | |||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -12.94 | -12.9 | -17.8 | -8.5 | |||||||||
cash-flows.row.acquisitions-net | -262.25 | 0 | 123.6 | 13.1 | |||||||||
cash-flows.row.purchases-of-investments | -1813.7 | -1813.7 | -1115 | -1422.9 | |||||||||
cash-flows.row.sales-maturities-of-investments | 2075.95 | 2075.9 | 991.5 | 1409.8 | |||||||||
cash-flows.row.other-investing-activites | 262.25 | 0 | -123.6 | -13.1 | |||||||||
cash-flows.row.net-cash-used-for-investing-activites | 249.31 | 249.3 | -141.4 | -21.6 | |||||||||
cash-flows.row.debt-repayment | 0 | 0 | -3.1 | -3.7 | |||||||||
cash-flows.row.common-stock-issued | 17.82 | 17.8 | 296.2 | 19.3 | |||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.other-financing-activites | 17.82 | 17.8 | 17.6 | 3.7 | |||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 17.82 | 17.8 | 310.7 | 19.3 | |||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -0.1 | 0 | 0 | |||||||||
cash-flows.row.net-change-in-cash | -90.86 | -90.9 | -75.4 | -213.7 | |||||||||
cash-flows.row.cash-at-end-of-period | 479.87 | 127.1 | 219.5 | 295 | |||||||||
cash-flows.row.cash-at-beginning-of-period | 570.73 | 218 | 295 | 508.6 | |||||||||
cash-flows.row.operating-cash-flow | -357.99 | -358 | -244.7 | -211.4 | |||||||||
cash-flows.row.capital-expenditure | -12.94 | -12.9 | -17.8 | -8.5 | |||||||||
cash-flows.row.free-cash-flow | -370.93 | -370.9 | -262.5 | -219.9 |
Wiersz rachunku zysków i strat
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 330.53 | 330.5 | 108.5 | 48.7 | |||||||||
income-statement-row.row.cost-of-revenue | 14.92 | 16.7 | 7 | 5.6 | |||||||||
income-statement-row.row.gross-profit | 315.61 | 313.8 | 101.4 | 43.1 | |||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.research-development | 423.88 | - | - | - | |||||||||
income-statement-row.row.selling-general-administrative | 103.35 | - | - | - | |||||||||
income-statement-row.row.selling-and-marketing-expenses | -2.18 | - | - | - | |||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.operating-expenses | 525.05 | 510.5 | 449.2 | 344.4 | |||||||||
income-statement-row.row.cost-and-expenses | 527.23 | 527.2 | 449.2 | 344.4 | |||||||||
income-statement-row.row.interest-income | 51.51 | 51.5 | 14.8 | 4.6 | |||||||||
income-statement-row.row.interest-expense | -21.08 | 0 | 14.8 | 0 | |||||||||
income-statement-row.row.selling-and-marketing-expenses | -2.18 | - | - | - | |||||||||
income-statement-row.row.total-other-income-expensenet | 51.51 | 51.5 | 14.8 | 4.6 | |||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.total-operating-expenses | 51.51 | 51.5 | 14.8 | 4.6 | |||||||||
income-statement-row.row.interest-expense | -21.08 | 0 | 14.8 | 0 | |||||||||
income-statement-row.row.depreciation-and-amortization | 16.73 | 16.7 | 10.4 | 8.6 | |||||||||
income-statement-row.row.ebitda-caps | -192.31 | - | - | - | |||||||||
income-statement-row.row.operating-income | -196.7 | -196.7 | -340.7 | -295.8 | |||||||||
income-statement-row.row.income-before-tax | -145.19 | -145.2 | -326 | -291.2 | |||||||||
income-statement-row.row.income-tax-expense | -12.3 | 0 | 0 | -0.6 | |||||||||
income-statement-row.row.net-income | -145.22 | -145.2 | -326 | -290.6 |
Często zadawane pytania
Ile wynosi Denali Therapeutics Inc. (DNLI) aktywów ogółem?
Denali Therapeutics Inc. (DNLI) całkowite aktywa to 1153917000.000.
Jaki jest roczny przychód przedsiębiorstwa?
Roczny przychód to 1267000.000.
Jaka jest marża zysku firmy?
Marża zysku firmy to 0.955.
Czym są wolne przepływy pieniężne firmy?
Wolne przepływy pieniężne to -2.683.
Jaka jest marża zysku netto przedsiębiorstwa?
Marża zysku netto to -0.439.
Jaki jest całkowity przychód firmy?
Całkowity przychód to -0.595.
Co to jest Denali Therapeutics Inc. (DNLI) zysk netto (dochód netto)?
Zysk netto (dochód netto) wynosi -145224000.000.
Jakie jest całkowite zadłużenie firmy?
Całkowite zadłużenie to 52241000.000.
Ile wynoszą koszty operacyjne?
Wydatki operacyjne to 510504000.000.
Jaka jest wartość gotówki firmy?
Środki pieniężne przedsiębiorstwa to 127106000.000.